z-logo
open-access-imgOpen Access
Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy
Author(s) -
Betül Dündar,
Burcu Dinçgez Çakmak,
Gülten Özgen,
Fatma Ketenci Gencer,
Burcu Aydın Boyama
Publication year - 2017
Publication title -
the european research journal
Language(s) - English
Resource type - Journals
ISSN - 2149-3189
DOI - 10.18621/eurj.304373
Subject(s) - medicine , mucositis , methotrexate , lethargy , bone marrow suppression , vomiting , ectopic pregnancy , rash , bone marrow , leukopenia , surgery , nausea , chemotherapy , gastroenterology , pregnancy , biology , genetics
Methotrexate is associated with multisystem side effects which depend on the dosage, route of administration and length of treatment. Bone marrow suppression is a very rare but one of the most mortal complications. A case of severe bone marrow suppression following single dose methotrexate for ectopic pregnancy was presented in this study. A 33-year-old woman, diagnosed as ectopic pregnancy, was given single-dose intramuscular methotrexate of 50 mg/m². On 10 th day patient was admitted with lethargy, irritability, vomiting, hematemesis, diarrhea, oral mucositis and skin rash. Laboratory findings revealed severe bone marrow suppression. Supportive treatment together with antibacterial/ antifungal drugs and granulocyte colony stimulating factors were administered. On the 3 rd day of treatment, mucositis and oral intake began to improve. After 1 week complete blood count was normal. Methotrexate may have mortal clinical consequences even with very low doses. Therefore, a careful patient history for patient selection and closer clinical follow-up are essential.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom